

# Resource Summary Report

Generated by RRID on Sep 8, 2026

## LL/2-Luc2

RRID:CVCL\_A4CM

Type: Cell Line

---

### Proper Citation

ATCC Cat# CRL-1642-LUC2, RRID:CVCL\_A4CM

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_A4CM](https://web.expasy.org/cellosaurus/CVCL_A4CM)

**Proper Citation:** ATCC Cat# CRL-1642-LUC2, RRID:CVCL\_A4CM

**Description:** Cell line LL/2-Luc2 is a Cancer cell line with a species of origin Mus musculus (Mouse)

**Disease:** Malignant tumors of the mouse pulmonary system

**Comments:** Characteristics: Stably expresses firefly luciferase under the control of the human EF1a promoter (ATCC=CRL-1642-LUC2).

**Category:** Cancer cell line

**Organism:** Mus musculus (Mouse)

**Name:** LL/2-Luc2

**Cross References:** ATCC:CRL-1642-LUC2, Wikidata:Q105509912

**ID:** CVCL\_A4CM

**Vendor:** ATCC

**Catalog Number:** CRL-1642-LUC2

**Hierarchy:** cvcl\_4358

**Record Creation Time:** 20250130T072048+0000

**Record Last Update:** 20260905T184050+0000

---

### Ratings and Alerts

No rating or validation information has been found for LL/2-Luc2.

No alerts have been found for LL/2-Luc2.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Koltun B, et al. (2025) Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance. *Molecular cancer therapeutics*, 24(11), 1815.

Nyberg WA, et al. (2023) An evolved AAV variant enables efficient genetic engineering of murine T??cells. *Cell*, 186(2), 446.

Deng H, et al. (2022) A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. *Cancer research*, 82(19), 3561.

Kato T, et al. (2021) Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. *Molecular cancer therapeutics*, 20(11), 2262.